BEAUFORT, S.C., July 18, 2025–(BUSINESS WIRE)–A new report published by THE SAGE GROUP quantifies CVD prevalence and incidence for the 2020-2040 period.
“Chronic venous disease afflicts 1.5 times as many people as all cardiovascular diseases combined, and five times more than those with diabetes. It is one of the most prevalent chronic diseases. However, CVD is significantly underestimated, underdiagnosed and undertreated,” stated Mary L. Yost, President.
CVD represents a spectrum of medical conditions involving morphological and functional abnormalities of the venous system. Severity ranges from mild disease such as spider veins, reticular veins and telangiectasia to active venous ulcers. The most severe stage of CVD, chronic venous insufficiency (CVI), is characterized by edema, skin changes and ulcers.
Commenting on CVI, Yost observed, “The primary causes are damaged or incompetent ‘refluxing’ valves and obstructions due to deep vein thrombosis (DVT). CVI is strongly associated with cardiovascular disease sharing many risk factors. CVI increases the risk of all-cause mortality by 3X.”
“If untreated, CVI progresses to more severe disease, including venous ulcers. In 2025, over 2 million individuals suffer from venous ulcers generating direct medical costs of $55 to $70 billion,” Yost continued.
“Our venous disease estimates are higher than most of the commonly quoted numbers,” Yost stated. “Our review of the literature concluded that many of the frequently quoted, older studies have significant limitations. This is especially true for venous ulcers with widely varying incidence and prevalence estimates. Venous ulcers are frequently underestimated because approximately half of patients self-treat.”
About the Report: Chronic Venous Disease (CVD) Epidemiology, Prevalence, Incidence and Progression
The report focuses on CVD epidemiology, prevalence, incidence and the percent progression to more severe disease. The primary purpose of this research is to estimate the number of U.S. adults with CVD, the number with CVI and the number in each of the C1-C6 CEAP classes.
Patient prevalence and incidence estimates for the 2020-2040 period are provided in 5-year increments.
Additional information: https://www.thesagegroup.us/reports/chronic-venous-disease-cvd-epidemiology-prevalence-incidence-and-progression/.
THE SAGE GROUP, a research and consulting company, specializes in arterial and venous disease in the lower limbs.
Additional information: www.thesagegroup.us.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250718559060/en/